Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IDP-122 Lotion
IDP-122 · 2 trials · 1 indication
Treatment success defined as at least a 2-grade improvement from Baseline in the IGA score and an IGA score equating to "clear" or "almost clear" at Week 8. The IGA score was based on a 5-point scale ranging from 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe). The face, scalp, palms, soles, axillae, and intertriginous areas were excluded from this assessment.
| Arm | Type | Description |
|---|---|---|
| IDP-122 Lotion | EXPERIMENTAL | Participants will apply IDP-122 Lotion (halobetasol propionate \[HP\] 0.01%) topically once daily for 8 weeks. |
| IDP-122 Vehicle Lotion | ACTIVE_COMPARATOR | Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks. |
| Name | Type | Description |
|---|---|---|
| IDP-122 Lotion | DRUG | Topical lotion |
| IDP-122 Vehicle Lotion | DRUG | Topical lotion. No active ingredient. |
Key Inclusion Criteria: * Male or female, of any race, at least 18 years of age (inclusive). * Freely provides both verbal and written informed consent. * Has an area of plaque psoriasis appropriate for topical treatment that covers a body surface area (BSA) of at least 3%, but no more than 12%. Th...
IDP-122 is an investigational small molecule lotion being developed for the treatment of plaque psoriasis. It is also known as IDP-122 Lotion. Bausch Health Companies Inc. (ticker BHC) is developing the asset, which has completed Phase 3 clinical development in adults with plaque psoriasis.
IDP-122 is being studied for the treatment of plaque psoriasis, a common inflammatory skin condition. Both completed Phase 3 trials enrolled adults 18 years and older with plaque psoriasis in the United States. The program has not reported an approved indication, so the use remains investigational.
IDP-122 is developed by Bausch Health Companies Inc., which trades under the ticker BHC. The company sponsored the Phase 3 plaque psoriasis program for the asset, including the two completed trials that together enrolled 430 participants in the United States.
IDP-122 has completed Phase 3 development for plaque psoriasis. Two Phase 3 trials, both randomized, double-blind and placebo-controlled, have finished, and no trials are currently listed as active. The asset is investigational and has not been approved for marketing based on the information available.
IDP-122 was studied in two completed Phase 3 trials in plaque psoriasis: NCT02515097, which enrolled 213 participants, and NCT02514577, which enrolled 217 participants. Both were randomized, double-blind, placebo-controlled studies conducted in the United States in adults aged 18 years and older.
Yes, IDP-122 Lotion is another name for IDP-122. The two names refer to the same investigational small molecule product developed by Bausch Health Companies Inc. for plaque psoriasis, so searches for either name point to the same Phase 3 asset.